Learn about product launches and treatment options at the Industry Theaters and Mini Industry Theaters.
ATS 2016 will deliver several Industry Theater and Mini Industry Theater discussions in the Exhibit Hall Sunday through Tuesday. Have lunch while learning about new product launches and treatment options. Complimentary boxed lunch will be provided by the ATS while supplies last.
Sunday
Mini Industry Theater
11:30 a.m.-Noon
Is It a Clot? The Progression From PE to CTEPH
Chronic thromboembolic pulmonary hypertension (CTEPH) is the only potentially curable (via pulmonary thromboendarterectomy, PTE) form of pulmonary hypertension (PH). Because it is potentially curable, it’s vitally important that CTEPH not be mistaken for other forms of PH or for a “chronic” pulmonary embolism (PE) or “unresolved clot.”
A leading CTEPH expert will discuss
- How an acute PE can lead to CTEPH
- The signs and symptoms that should lead one to suspect CTEPH in a patient who has had an acute PE
- Preferred screening tests and steps for confirming a CTEPH diagnosis
- The importance of engaging an experienced CTEPH team to assess patients as candidates for PTE surgery
Attendees will better understand CTEPH and its relation to acute PE, and they will appreciate the importance of reasonable suspicion, accurate diagnosis, and timely referral to an experienced center.
Speaker: Ivan Robbins, MD, Professor of Medicine, Director, Adult Pulmonary Vascular Center, Vanderbilt University Medical Center
Company: Bayer
Industry Theater 1
11:30 a.m.-12:15 p.m.
Multidisciplinary Views on the Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) Learning Theater
Join an expert pulmonologist and radiologist for a multidisciplinary presentation about the diagnosis and management of IPF. Attendees will gain an increased understanding of IPF and its clinical presentation while taking a deeper dive into the challenges associated with making the IPF diagnosis.
Company: Genentech Inc.
Mini Industry Theater
12:30-1 p.m.
Parenteral Prostacyclin: Who, When, and How?
In light of various therapy options, who is appropriate for parenteral prostacyclin treatment? Join us for a live presentation where we will discuss variables you can use to identify appropriate patients, at the appropriate point in treatment, and how to optimize the conversation. This presentation is open to all ATS 2016 International Conference attendees.
Company: United Therapeutics Corporation
Industry Theater 1
1:15-2 p.m.
Can We Personalise and Simplify COPD Management?
As more treatments for COPD become available for patients, ensuring the right patient receives the right medicine for their disease will be key to optimizing their care. The focus of this Industry Theater will be to discuss treatment options to prevent short term deterioration and the issues of personalising treatment for COPD patients.
- 1:15 p.m. Welcome and introductions—Neil Barnes, London, UK
- 1:20 p.m. The importance of preventing short term deterioration; optimizing bronchodilatation—Ian Naya, London, UK
- 1:35 p.m. Towards a more tailored approach to COPD management—Paul Jones, London, UK
- 1:50 p.m. Questions and answers—Neil Barnes, London, UK
Company: GlaxoSmithKline Ltd.
Industry Theater 2
1:15-2 p.m.
Targeting Exacerbations in Moderate to Severe Persistent Allergic Asthma
This program features a presentation on Targeting Exacerbations in Moderate to Severe Persistent Allergic Asthma. Complimentary lunch is provided.
Objectives:
- Discuss current challenges in identifying patients with uncontrolled allergic asthma
- Review case studies and clinical data
- Treatment of moderate to severe persistent allergic asthma
- Review efficacy and safety data for a treatment option for appropriate patients with uncontrolled allergic asthma
Companies: Genentech USA Inc. and Novartis Pharmaceuticals Corporation
Mini Industry Theater
1:30-2 p.m.
Role and Clinical Application of an Oral Prostacyclin Class Therapy in the Early Treatment of Pulmonary Arterial Hypertension
With prostacyclin class therapy being recommended for treatment of PAH for more than a decade, this session will focus on the use of an oral prostacyclin class therapy in the early treatment of PAH. Discussion will review the clinical data and practical applications for initiating an oral prostacyclin class therapy in prostacyclin naïve or stable parenteral patients.
Company: United Therapeutics Corporation
Monday
Mini Industry Theater
11:30 a.m.-Noon
Role and Clinical Application of an Oral Prostacyclin Class Therapy in the Early Treatment of Pulmonary Arterial Hypertension
With prostacyclin class therapy being recommended for treatment of PAH for more than a decade, this session will focus on the use of an oral prostacyclin class therapy in the early treatment of PAH. Discussion will review the clinical data and practical applications for initiating an oral prostacyclin class therapy in prostacyclin naïve or stable parenteral patients.
Company: United Therapeutics Corporation
Industry Theater 1
11:30 a.m.-12:15 p.m.
Multidisciplinary Views on the Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)Learning Theater
Join an expert pulmonologist and radiologist for a multidisciplinary presentation about the diagnosis and management of IPF. Attendees will gain an increased understanding of IPF and its clinical presentation while taking a deeper dive into the challenges associated with making the IPF diagnosis.
Company: Genentech, Inc.
Industry Theater 2
11:30 a.m.-12:15 p.m.
kNOw Your Patient Goals: Understanding the Goal-oriented Approach in PAH (WHO Group 1) and CTEPH (WHO Group 4)
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are characterized by elevated pulmonary artery pressures and increased pulmonary vascular resistance. Impaired synthesis of endogenous nitric oxide contributes to the pathology of both diseases. PH experts will present and discuss cases that demonstrate how targeting the NO-sGC-cGMP pathway can contribute to goal-oriented treatment approaches.
Speakers: Murali Chakinala, MD, Associate Professor of Medicine, Director, Pulmonary Hypertension Care Center, Co-Director, HHT Center of Excellence, Washington University School of Medicine; Rajeev Saggar, MD, Executive Director of Advanced Lung Disease Institute, Medical Director of Critical Care, Associate Clinical Professor of Medicine, University of Arizona
Company: Bayer
Mini Industry Theater
12:30-1 p.m.
Positive Airway Pressure and the Heart: Benefit or Harm
Discuss sleep-disordered breathing (SDB) that occurs in patients with congestive heart failure (CHF). Compare advanced positive airway pressure modalities in the management of SDB that occurs in patients with CHF. Examine recent research and discuss specific indications and limitations of servo ventilation.
Speaker: Professor Dr. Winfried Randerath, Chief Physician and Medical Director, Hospital Bethanien, Department of Pulmonology and Allergology, Solingen, Germany
Company: Philips Respironics, Inc.
Industry Theater 1
1:15-2 p.m.
Exploring the Significance of Early Lung Function Loss in COPD Maintenance Treatment: An Interactive Discussion
A dynamic, expert-led debate which will highlight the considerations that impact initial COPD maintenance treatment decisions.
Speakers: Gary T. Ferguson, MD, Director, Pulmonary Research, Institute of Southeast Michigan, Farmington Hills, Michigan; Donald P. Tashkin, MD, Emeritus Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Industry Theater 2
1:15-2 p.m.
Meet the FLAME Experts: Discussion Session
(open to non-U.S. attendees only)
During this Novartis supported mini industry theater, experts involved in the recently completed FLAME study will discuss key findings from the study, its importance in understanding the effects of indacaterol/glycopyrronium in high-risk patients, and the potential implications for treatment guidelines and clinical practice.
- 1:30-1:35 p.m. Introduction—Jim Donohue
- 1:35-1:40 p.m. FLAME study design—Don Banerji
- 1:40-1:50 p.m. FLAME data and potential implications—Ken Chapman
- 1:50-2 p.m. Q&A—All
Company: Novartis Pharma AG
Tuesday
Mini Industry Theater
11:30 a.m.-Noon
Managing COPD Exacerbations With the Experts
Managing exacerbations remains a challenge for patients with severe COPD. Join us for a dynamic case-based presentation led by an expert panel. The objective of this program is to provide health care professionals with insights into the complexities associated with COPD exacerbation management as well as strategies for reducing the risk of exacerbations in severe COPD patients.
Speakers: Donald P. Tashkin, MD, Professor Emeritus of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California; Ronald C. Balkissoon, MD, MSc, Pulmonary Consultant, Denver, Colorado
Company: AstraZeneca Pharmaceuticals Inc.
Industry Theater 1
11:30 a.m.-12:15 p.m.
Thrombosis: DVT/PE An Exploration in Risk Reduction
This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events.
Speaker: Joseph K. Choo, MD, FACC, Staff Cardiologist, Christ Hospital Physicians, Ohio Heart and Vascular, Cincinnati, Ohio
Company: Janssen Pharmaceuticals Inc.
Industry Theater 2
11:30 a.m.-12:15 p.m.
ORKAMBI® (lumacaftor/ivacaftor) Treatment Initiation and Clinical Management
Speaker: Manu Jain, MD, MSc, Northwestern University
Company: Vertex Pharmaceuticals Inc.
Mini Industry Theater
12:30-1 p.m.
COPD Is a Struggle. Let’s Talk About a Maintenance Therapy Option
The objective of this presentation is to provide pertinent, balanced information to health care professionals on the efficacy and safety of nebulized long-acting bronchodilator therapy for patients with COPD. It is designed to afford health care professionals the opportunity to review, evaluate, and discuss the role of nebulized long-acting bronchodilator therapy as an option for patients with COPD, including chronic bronchitis and emphysema, in order to make informed treatment decisions for their patients.
Speaker: Antonio Anzueto, MD, Professor of Medicine, University of Texas, Health Science Center at San Antonio, San Antonio, Texas
Company: Sunovion Pharmaceuticals Inc.
Industry Theater 1
1:15-2 p.m.
Insights in IPF: Perspectives on the Disease and Its Diagnosis
Join us for a 45-minute Insights in IPF educational program examining the evolving understanding of idiopathic pulmonary fibrosis (IPF), including the science of the disease and the complexity of diagnosis. An expert in the field of interstitial lung disease will provide insight into the challenges of managing a patient with IPF, with perspectives on how to address these challenges in the clinic.
Speaker: Amy M. Olson MD, MSPH, National Jewish Health
Company: Boehringer Ingelheim Pharmaceuticals Inc.
Industry Theater 2
1:15-2 p.m.
Treatment Strategies for COPD Exacerbation Prevention: New Evidence
(open to non-U.S. attendees only)
During this Novartis-supported industry theater, a faculty of world-renowned experts will explore the burden of COPD exacerbations and new evidence for exacerbation prevention in high-risk patients with dual bronchodilator indacaterol/glycopyrronium. The potential implications of these data on the position of dual bronchodilators in COPD management also will be explored.
Speakers:
- 5 minutes: Addressing COPD treatment goals: LABA/LAMA vs. LABA/ICS—Claus Vogelmeier (Chair)
- 10 minutes: Unmet needs in COPD management: The importance of exacerbations and their prevention—Nicolas Roche
- 5 minutes: Piecing the evidence together: Treating high-risk patients—Claus Vogelmeier
- 15 minutes: Preventing exacerbations in high-risk patients: New evidence—Ken Chapman
- 5 minutes: Implications of new evidence with LABA/LAMA for the treatment of COPD—Claus Vogelmeier
- 5 minutes: Q&A: All
Company: Novartis Pharma AG
Mini Industry Theater
1:30-2 p.m.
COPD Disease Management to Reduce Hospital Readmissions
Discuss a program to reduce hospital readmissions for the COPD patient.
Speaker: Dr. Sai Parthasarthy
Company: Philips Respironics Inc.